Artwork

Content provided by Water Tower Research. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Water Tower Research or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Aspira Women’s Health CEO Nicole Sandford on OvaWatch Progress and Recent Financing

35:50
 
Share
 

Manage episode 429334557 series 3486351
Content provided by Water Tower Research. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Water Tower Research or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Send us a text

Aspira CEO and Director Nicole Sandford joins the Water Tower Hour Podcast to discuss recent updates on OvaSuite, including preliminary 2Q24 OvaWatch volume growth and the launch of mass monitoring. She walks us through what is driving OvaWatch growth and the messaging to physicians and patients around the value of proper malignancy risk assessment prior to surgical intervention. In addition, she reviews the recent private placement financing and potential opportunities for the company’s biobank of patient samples, including academic collaborations.

  continue reading

81 episodes

Artwork
iconShare
 
Manage episode 429334557 series 3486351
Content provided by Water Tower Research. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Water Tower Research or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Send us a text

Aspira CEO and Director Nicole Sandford joins the Water Tower Hour Podcast to discuss recent updates on OvaSuite, including preliminary 2Q24 OvaWatch volume growth and the launch of mass monitoring. She walks us through what is driving OvaWatch growth and the messaging to physicians and patients around the value of proper malignancy risk assessment prior to surgical intervention. In addition, she reviews the recent private placement financing and potential opportunities for the company’s biobank of patient samples, including academic collaborations.

  continue reading

81 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide